Metsera appoints Jon Stonehouse to Board and Matt Lang as Chief Legal Officer

Metsera, Inc.

Jon P. Stonehouse appointed to Board (Class III) and Audit Committee effective April 28, 2025.
Matthew Lang appointed Chief Legal Officer and Secretary; previously CBO/CLO at Lyell Immunopharma.
Stonehouse receives option award vesting in 36 equal monthly installments under director comp plan.
Stonehouse is CEO of BioCryst Pharmaceuticals; brings M&A and pharma leadership experience.
Lang's background includes executive roles at Myovant Sciences and Gilead Sciences.

item 5.02 item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jon P. Stonehouse

Director

Metsera, Inc.

Effective: 2025-04-28
Filed: April 28, 2025, 7:59 PM ET

On April 28, 2025, the Board of Directors (the “Board”) of Metsera, Inc. (the “Company”) appointed Jon P. Stonehouse to the Company’s Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jon P. Stonehouse was appointed as Director at Metsera, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 28, 2025, the Board of Directors (the “Board”) of Metsera, Inc. (the “Company”) appointed Jon P. Stonehouse to the Company’s Board, effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-25-100859

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.